CLINICAL TRIALS PROFILE FOR INVERT SUGAR

All Clinical Trials for INVERT SUGAR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00896311 ↗	Intravenous (IV) Nitroglycerin for Versions in Nulliparous Women	Completed	University of Calgary	N/A	2003-03-01	Breech presentations (where a baby presents with feet or bottom down) have an increased risk of perinatal and neonatal complications, and are usually delivered by cesarean section. As an alternative, so that the baby can be delivered vaginally, an attempt can be made to turn the baby so that it is head down: this manoeuvre is called an external cephalic version (ECV). Drugs that relax the uterus (tocolytic agents) are sometimes used to help improve ECV success rates. Nitroglycerin is a tocolytic agent, but intravenous nitroglycerin has not been tested as an agent to help ECV. There is some suggestion that nitroglycerin may be more helpful in women who have not previously been pregnant (nulliparous women) than in women who have been pregnant more than once (multiparous women), and so we have planned two trials. This study is designed to answer the following questions for nulliparous women: Will administration of IV nitroglycerin for uterine relaxation improve ECV success rates? Will an increase in ECV success result in a decreased cesarean section rate?
NCT04470479 ↗	Oral Pilocarpine in the Treatment of the Dry Eye of Patients With Sjogrens Syndrome	Completed	Federal University of São Paulo	Phase 3	2005-03-01	The purpose of this study was to access the possible beneficial effects of oral use of pilocarpine in relieving signs and symptoms of patients with Sjogren's syndrome
NCT06233097 ↗	Esomeprazole Magnesium Dihydrate 40 mg Tablets Relative to Nexium 40 mg Tablets Under Fasting Condition	NOT_YET_RECRUITING	Bio-innova Co., Ltd	PHASE1	2024-08-29	The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be randomized, open-label, single dose, two way crossover design with two-period, two-treatment and two-sequence under fasting condition and at least 7 days washout period between the doses
NCT06233149 ↗	Esomeprazole Magnesium Dihydrate 40 mg Tablets Relative to Nexium 40 mg Tablets Under Fed Condition	NOT_YET_RECRUITING	Bio-innova Co., Ltd	PHASE1	2024-10-01	The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be randomized, open-label, single dose, full replicate crossover design with four-period, two-treatment, and two-sequence under fed condition and at least 7 days washout period between the doses.
NCT06477692 ↗	Invert-Prospective Phase II Randomized Trial of Involved Nodal Versus Elective Neck RadioTherapy	RECRUITING	National Cancer Institute (NCI)	PHASE2	2024-11-14	To determine the risk of solitary elective volume recurrence following involved nodal radiotherapy (INRT) versus elective nodal irradiation (ENI)

Clinical Trial Conditions for INVERT SUGAR

Condition Name

Condition Name for INVERT SUGAR
Intervention	Trials
Healthy Subjects	2
Complication of Pregnancy	1
Dry Eye	1
Head and Neck Cancer	1

Condition MeSH

Condition MeSH for INVERT SUGAR
Intervention	Trials
Head and Neck Neoplasms	1
Sjogren's Syndrome	1
Keratoconjunctivitis Sicca	1
Dry Eye Syndromes	1

Clinical Trial Locations for INVERT SUGAR

Trials by Country

Trials by Country for INVERT SUGAR
Location	Trials
United States	1
Brazil	1
Canada	1
China	1

Trials by US State

Trials by US State for INVERT SUGAR
Location	Trials
Texas	1

Clinical Trial Progress for INVERT SUGAR

Clinical Trial Phase

Clinical Trial Phase for INVERT SUGAR
Clinical Trial Phase	Trials
PHASE2	1
PHASE1	3
Phase 3	1

Clinical Trial Status

Clinical Trial Status for INVERT SUGAR
Clinical Trial Phase	Trials
NOT_YET_RECRUITING	2
Completed	2
ENROLLING_BY_INVITATION	1

Clinical Trial Sponsors for INVERT SUGAR

Sponsor Name

Sponsor Name for INVERT SUGAR
Sponsor	Trials
Bio-innova Co., Ltd	2
Federal University of São Paulo	1
National Cancer Institute (NCI)	1

Sponsor Type

Sponsor Type for INVERT SUGAR
Sponsor	Trials
Other	4
INDUSTRY	2
NIH	1

Clinical Trials Update, Market Analysis, and Projection for INVERT SUGAR

Last updated: May 6, 2026

What is “Invert Sugar” from a clinical-trials perspective?

“Invert sugar” is a food ingredient, not a single defined small-molecule or biologic drug product. It is typically a mixture of glucose and fructose generated by hydrolysis of sucrose. Because it is not a conventional patented therapeutic with a single active ingredient definition, “invert sugar” does not map cleanly to drug-indication clinical trial programs in standard registries (e.g., ClinicalTrials.gov) in a way that supports a drug-like development and IP-driven market projection.

Implication for clinical-trials update: A defensible “drug clinical trials update” requires a specific investigational product (brand, formulation, route, manufacturer) tied to registrable indications and measurable endpoints. With only “invert sugar” as the input term, that mapping cannot be completed to a specific clinical development pipeline.

Implication for market projection: Invert sugar sits in the commodity/food-ingredient market, where pricing, volumes, and trade flows dominate. Drug-style forecasts (peak sales by indication, patient numbers, label expansion, dosing, payer coverage) do not apply without product-specific therapeutic targeting.

Do clinical trials exist for invert sugar as a drug?

No complete and accurate drug-style clinical trial update can be produced from the term alone.

• Clinical trial registries generally record investigational products with precise names and indications.
• “Invert sugar” is usually categorized under food ingredients and sweeteners, not investigational therapeutics.
• Without a defined investigational drug product name (formulation, route, sponsor, indication), it is not possible to produce a complete, accurate, registry-grounded update.

What is the market for invert sugar (ingredient category), and what drives it?

Invert sugar is sold as a sweetener ingredient used in foods and confectionery (e.g., baked goods, sauces, candy) because it provides functional sweetness and affects crystallization and moisture retention versus sucrose in many formulations.

Demand drivers

• Confectionery and bakery growth: Invert sugar is used to control texture and prevent crystallization in sugar-based products.
• Reformulation and performance requirements: Manufacturers choose invert sugar to meet handling and shelf-life targets.
• Sweetener substitution dynamics: Markets shift among sucrose, high-fructose syrups, glucose syrups, and invert sugar based on input costs, regulation, and consumer taste profiles.

Supply and pricing structure (ingredient category)

• Invert sugar supply typically tracks:
  • Feedstock sucrose availability
  • Hydrolysis and refining costs
  • Regional production capacity and trade
• Price formation behaves like other sweeteners: it is influenced more by commodity economics than by clinical adoption cycles.

Market projection for “invert sugar”

A drug-style projection cannot be produced.

To project “invert sugar” as a drug, the analysis must be tied to:

• a therapeutic indication
• dosing regimen and route
• trial readouts and endpoints
• regulatory status (IND/NDA or similar)
• reimbursement and pricing
• market size defined in patients and treatment courses

None of these are definable from “invert sugar” as a term.

Where does this leave an investment-grade view?

An investment-grade projection is feasible only if “INVERT SUGAR” corresponds to a specific patented or branded therapeutic product. With the provided term, that product identity cannot be established to a clinical or regulatory development track, so no credible projection can be computed.

Actionable decision framing (what can be done with the available definition)

Given the inability to anchor “invert sugar” to a drug development pipeline or drug sales forecast, the only decision-grade use is category-level ingredient market analysis (sweeteners). That requires a different scope than a clinical trials update and drug market projection.

• Clinical trials update: Not producible as a drug program based on the term alone.
• Drug market projection: Not producible without therapeutic indication and regulatory path.
• Ingredient market analysis: Would be produced as a sweetener commodity report (volumes, import-export, capacity, and price drivers), not as a clinical-driven forecast.

---

Key Takeaways

• “Invert sugar” is a food sweetener ingredient (glucose-fructose mixture), not a clearly defined drug product.
• A drug-style clinical trials update and drug sales projection cannot be produced from the term alone because it does not map to an investigational drug identity with indications, endpoints, and regulatory milestones.
• Any projection must be reframed as an ingredient (sweetener) market analysis, not a therapeutic forecast.

---

FAQs

1. Is invert sugar a prescription drug?
   No. Invert sugar is typically used as a food ingredient and sweetener.

2. Why can’t there be a standard “clinical trials update” for invert sugar?
   Clinical trial registries require an investigational product and indication; “invert sugar” is not inherently a drug identity.

3. What market does invert sugar belong to?
   The sweeteners/food ingredients market.

4. What would make a drug-style projection possible for invert sugar?
   A specific therapeutic formulation and indication tied to sponsor-led clinical development and regulatory submissions.

5. How does invert sugar’s market differ from pharma markets?
   It is driven by formulation demand, commodity economics, and trade dynamics rather than clinical efficacy, patient uptake, and reimbursement.

---

References (APA)

[1] U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov. https://clinicaltrials.gov/
[2] FDA. (n.d.). Food labeling and sweeteners resources. https://www.fda.gov/